Tumor-derived small extracellular vesicles loaded with functionally active miR-34a mimic can modify the anti-tumor response in 4T1 breast cancer animal model
Totally, tsEV could be considered as a delivery carrier for miR-34a replacement therapy which also provided an anti-tumor immune response against 4T1- tumor. Thus, this platform could be considered a complementary approach to TNBC therapy.
Authors
- Bahare Niknam
- Davar Amani (ORCID: https://orcid.org/0000-0001-7277-4484)
- Kaveh Baghaei (ORCID: https://orcid.org/0000-0003-2102-9729)
- Nariman Mosaffa (ORCID: https://orcid.org/0000-0003-1695-782X)
- Maryam Hosseini (ORCID: https://orcid.org/0000-0002-7482-6185)
- Mahsa Hajivalili (ORCID: https://orcid.org/0000-0003-1771-511X)
- Mohsen Rastegari Pouyani
Institutions
- Hamedan University of Medical Sciences (IR)
- Iran University of Medical Sciences (IR)
- Shiraz University of Medical Sciences (IR)
- Shahid Beheshti University of Medical Sciences (IR)
Publication Details
- Journal
- Cancer Cell International
- Published
- 2025-10-14
- DOI
- https://doi.org/10.1186/s12935-025-03994-6
- Citations
- 1
- Primary Topic
- Extracellular vesicles in disease
- Type
- article
- Field-Weighted Citation Impact
- 0.81
Funders
- Shahid Beheshti University of Medical Sciences